Hence, Ag-scaffold–driven T-Ag–specific T cell expansion can be used to enhance CD8+ T cell reactivity to these critical tumor Ags and establish a T cell effector pool even from patients with no detectable T-Ag–specific T cells prior to expansion. The gene discussed is CD8A; the disease is neoplasm.